Physician profile
Michael Nieder
NPI 1295710218
$74,940.22
in general payments reported to CMS, 2019-2025
5 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $3,774 · 2021: $9,254 · 2022: $4,215 · 2023: $21K · 2024: $14K · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $4,728 · Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,760.00 |
| Travel and Lodging | $4,727.99 |
| Food and Beverage | $1,442.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $73,987.84 | 2019-2024 | |
| Viiv Healthcare Company | $453.98 | 2024-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $409.02 | 2024-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $59.39 | 2024-2025 | Delstrigo, Pifeltro |
| Astellas Pharma US INC | $29.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nieder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.